Side-by-side comparison of AI visibility scores, market position, and capabilities
Metabolic health program combining continuous glucose monitoring with nutrition coaching; prediabetes prevention for employer wellness programs competing with Virta Health and Omada.
Gradia Health is a digital health company providing personalized metabolic health programs that combine continuous glucose monitoring (CGM), one-on-one nutrition coaching, and lifestyle interventions to prevent and reverse chronic metabolic conditions including prediabetes, insulin resistance, and metabolic syndrome. Founded in 2020 in San Francisco, Gradia raised $4.33-6.83 million in funding and generated $1.1 million in revenue in 2024, serving patients through both employer-sponsored health benefits and direct-to-consumer program enrollment.\n\nGradia's program pairs participants with a continuous glucose monitor that provides real-time blood sugar data, then connects them with registered dietitians and health coaches who use that data to personalize meal plans and behavioral interventions. The CGM data reveals how individual participants' blood sugar responds to specific foods, exercise, sleep, and stress — enabling precision nutrition recommendations that go beyond generic dietary guidelines. Programs typically run 3-6 months and focus on sustainable lifestyle changes supported by regular coach check-ins.\n\nIn 2025, Gradia operates in the rapidly growing metabolic health digital platform market alongside Levels Health (CGM for optimization), Virta Health (type 2 diabetes reversal), Noom (behavioral weight loss), and Omada Health (preventive health coaching) for the employer wellness and direct-to-consumer metabolic health programs. The employer-sponsored wellness market is particularly active as self-insured employers recognize that preventing metabolic disease is significantly cheaper than treating its downstream consequences (heart disease, type 2 diabetes, kidney disease). Gradia's 2025 strategy focuses on growing employer contracts with self-insured mid-market companies, deepening the CGM-based coaching methodology with AI-powered insights, and expanding the clinical evidence base for the program's outcomes.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.